共 7 条
[1]
Yewdell JW(2021)Antigenic drift: understanding COVID-19 Immunity 54 2681-2687
[2]
Andrews N(2022)Duration of protection against mild and severe disease by Covid-19 vaccines N Engl J Med 386 340-350
[3]
Barda N(2021)Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting N Engl J Med 385 1078-1090
[4]
Munro APS(2021)Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Lancet 398 2258-2276
[5]
Accorsi EK(2022)Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-coV-2 omicron and delta variants JAMA 385 1196-1206
[6]
Nathan P(2021)Overall survival benefit with tebentafusp in metastatic uveal melanoma N Engl J Med 385 2219-2229
[7]
Lebwohl MG(2021)Phase 3 trials of tapinarof cream for plaque psoriasis N Engl J Med undefined undefined-undefined